Janssen's new depression drug Spravato can be prescribed at general hospitals.

According to related industries, in addition to Big5 such as SMC and SNUH, Kyunghee University Hospital, Kyungpook National University Hospital, Pusan ​​Paik Hospital, Chung-Ang University Hospital, Jeju National University Hospital, and Haeundae Paik Hospital have passed DC of Spravato (Esketamine), which is used as a combination therapy with oral antidepressants.

Spravato, approved in Korea in June last year, is the first Nasal Spray in the field of treatment-resistant depression and the first in 30 years in the field of major depressive disorders.

Spravato (Esketamine) improves s